Pancreatic Cancer Research

ResearcherWuhan UniversityNo recent work listed

Jing Tao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3914-8785; OpenAlex author ID A5100763091. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
14
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper

Papers 8

  1. CASC9 potentiates gemcitabine resistance in pancreatic cancer by reciprocally activating NRF2 and the NF-κB signaling pathway. Last author DOI 10.1007/s10565-022-09746-w↗
  2. microRNA-21-5p from M2 macrophage-derived extracellular vesicles promotes the differentiation and activity of pancreatic cancer stem cells by mediating KLF3. Last author DOI 10.1007/s10565-021-09597-x↗
  3. Identifying a novel IRF3/circUHRF1/miR-1306-5p/ARL4C axis in pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1080/15384101.2021.2020450↗
  4. Circular RNA CDR1as promotes tumor progression by regulating miR-432-5p/E2F3 axis in pancreatic cancer. Co-author DOI 10.1186/s12935-021-01812-3↗
  5. Hypoxia-induced lncRNA CASC9 enhances glycolysis and the epithelial-mesenchymal transition of pancreatic cancer by a positive feedback loop with AKT/HIF-1α sig… Last author PMID 33520364↗
  6. LINC00052 functions as a tumor suppressor through negatively modulating miR-330-3p in pancreatic cancer. Last author DOI 10.1002/jcp.28209↗
  7. MicroRNA-374 targets JAM-2 regulates the growth and metastasis of human pancreatic cancer cells. Co-author PMID 31737197↗
  8. Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling. Last author DOI 10.1186/s13046-018-0972-3↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hanjun Li · 4 shared papers, 2021–2023 · strength 0.65
  2. Xingcheng Xiong · 4 shared papers, 2019–2022 · strength 0.61
  3. Jian Hua Chang · 4 shared papers, 2019–2022 · strength 0.59
  4. Zhi‐Gang Tang · 3 shared papers, 2018–2023 · strength 0.41
  5. Zhengle Zhang · 3 shared papers, 2018–2023 · strength 0.41
  6. Pei Mei · 2 shared papers, 2021–2022 · strength 0.29
  7. Longjiang Chen · 1 shared paper, 2023 · strength 0.20
  8. Weimin Hu · 1 shared paper, 2022 · strength 0.17
  9. Zhilin Zhou · 1 shared paper, 2022 · strength 0.16
  10. Wei Liu · 1 shared paper, 2022 · strength 0.16
  11. Weixing Wang · 1 shared paper, 2019 · strength 0.12
  12. Hehe Li · 1 shared paper, 2021 · strength 0.12
  13. Wei Li · 1 shared paper, 2019 · strength 0.11
  14. Kongfan Zhu · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.